Clinical trials: Dupilumab
Atopic Dermatitis
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Start Up (NCT06461897)
- Testing
- Upadacitinib, Dupilumab
- Where
- 150 sites in United States, Argentina and 24 more
- Volunteers
- 699 people
- Sponsor
- AbbVie
Pruritis
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.
- Trial name
- NCT06226610
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Akron Children's Hospital
Peanut Allergy
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Primary objective is to assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the proportion of participants who pass a post up-dosing…
- Trial name
- NCT03682770
- Testing
- Dupilumab, AR101
- Where
- 25 sites in United States
- Volunteers
- 148 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps
Primary Objective: To evaluate the efficacy of dupilumab 300 milligram (mg) every 2 weeks (q2w) compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity…
- Trial name
- SINUS-24 (NCT02912468)
- Testing
- Dupilumab SAR231893 (REGN668), Mometasone furoate 50 micrograms
- Where
- 76 sites in United States, Bulgaria and 11 more
- Volunteers
- 276 people
- Sponsor
- Sanofi
Asthma
Investigating Dupilumab's Effect in Asthma by Genotype
The Goal of this study is to investigate if individuals ages 12 years and older, carrying the IL-4RαR576 gene variant, will have a greater response to therapy acting directly on the anti-IL-4R.
- Trial name
- IDEA (NCT03694158)
- Testing
- Dupilumab
- Where
- 6 sites in United States
- Volunteers
- 150 people
- Sponsor
- Boston Children's Hospital
Adverse Pregnancy Outcomes, Atopic Dermatitis
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of adverse infant outcomes (major congenital malformations [MCMs]…
- Trial name
- NCT03936335
- Testing
- dupilumab
- Where
- United States
- Volunteers
- 12,343 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation
Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate-or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by Annualized rate of acute moderate and severe COPD…
- Trial name
- BOREAS (NCT03930732)
- Testing
- Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist
- Where
- 275 sites in United States, Argentina and 22 more
- Volunteers
- 939 people
- Sponsor
- Sanofi
Asthma Control
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
This study tests whether an asthma medication called dupilumab can help people achieve complete asthma control (called "remission") when given earlier in their disease, before asthma becomes severe.
- Trial name
- HOTHOT (NCT07309614)
- Testing
- Dupilumab Prefilled Syringe
- Where
- 5 sites in Australia, Canada and 1 more
- Volunteers
- 150 people
- Sponsor
- Université de Sherbrooke
Chronic Sinusitis
Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
The overarching objective of this study is to determine the clinical effectiveness of dupilumab for the treatment of CRS that includes several potential disease endotypes with the exclusion of the nasal polyp cluster that has…
- Trial name
- NCT04362501
- Testing
- dupilumab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Johns Hopkins University
Atopic Dermatitis
IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis
The purpose of this study is to better understand the interactions between the innate immune system, in particular eosinophils, their secreted cytokines (interleukin-4), and metabolism in human health and disease states such as…
- Trial name
- NCT05372003
- Testing
- Dupilumab, Photo therapy
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Atopic Dermatitis, Eczema
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
The utility of functionally relevant signature genes in assessing the clinical outcomes of dupilumab treatment in the adult onset atopic dermatitis
- Trial name
- NCT04358224
- Testing
- Dupilumab Prefilled Syringe
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonathan A. Bernstein, MD
Atopic Dermatitis
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
This is a multicentre, prospective, non-interventional study that aims to describe the treatment patterns of in Atopic dermatitis (AD) patients aged 6 months to 11 years old in Spain: patients' characteristics, disease…
- Trial name
- PROADAP (NCT06415175)
- Testing
- Dupilumab
- Where
- 15 sites in Spain
- Volunteers
- 143 people
- Sponsor
- Sanofi
Alopecia Areata
Dupilumab in the Treatment of Pediatric Alopecia Areata
This is a prospective, randomized, double-blind, placebo-controlled clinical trial. The study will take place at four sites. This trial will enroll a total of 76 children and adolescents with moderate to severe AA (affecting at…
- Trial name
- PEDAL (NCT05866562)
- Testing
- Dupilumab
- Where
- 5 sites in United States
- Volunteers
- 76 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Dupilumab in Eosinophilic Gastritis
40 participants with Eosinophilic Gastritis 12-70 years of age will be randomly assigned with dupilumab or placebo subcutaneous injections every two weeks for a total of 12 weeks.
- Trial name
- NCT03678545
- Testing
- Dupilumab (blinded)
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Severe Asthma
Dupilumab for Severe Asthma in a Real Life Setting
Dupilumab is a monoclonal anti-IL-4/13Rα antibody developed for severe asthma (SA). In France, mepolizumab was commercialized in February 2018.
- Trial name
- DUPI-France (NCT04022447)
- Testing
- Dupilumab
- Where
- France
- Volunteers
- 86 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Food Allergy
Effectiveness of Dupilumab in Food Allergic Patients With Moderate to Severe Atopic Dermatitis
This study evaluates the effectiveness of Dupilumab in food allergic patients with moderate to severe Atopic Dermatitis (AD). Included patients participated in the BioDay Registry.
- Trial name
- NCT04462055
- Where
- Netherlands
- Volunteers
- 3 people
- Sponsor
- UMC Utrecht
Eosinophilic Esophagitis (EoE)
Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
The Primary objective is to demonstrate the efficacy of dupilumab treatment compared with placebo in pediatric patients with active eosinophilic esophagitis (EoE) based on histologic improvement meeting validated histologic…
- Trial name
- EoE KIDS (NCT04394351)
- Testing
- Dupilumab
- Where
- 27 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Smell Loss
Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
The goal of this observational study is to learn what can predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps being treated with dupilumab.
- Trial name
- NCT06892704
- Testing
- Dupilumab - Standard Dose
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Asthma, Allergic
Dupilumab Effects Against Aeroallergen Challenge
The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.
- Trial name
- NCT05720325
- Testing
- Dupilumab, House Dust Mites (HDM)
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Atopic Dermatitis
A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis
This study will evaluate upadacitinib compared to dupilumab (Dupixent®) in adults with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- Heads Up (NCT03738397)
- Testing
- Upadacitinib, Dupilumab
- Where
- 159 sites in United States, Australia and 21 more
- Volunteers
- 673 people
- Sponsor
- AbbVie